Freedman A, Afonja O, Chang MW, Mostashari F, Blaser M, Perez-Perez G, Lazarus H, Schacht R, Guttenberg J, Traister M, Borkowsky W. Cutaneous Anthrax Associated With Microangiopathic Hemolytic Anemia and Coagulopathy in a 7-Month-Old Infant. JAMA. 2002;287(7):869–874. doi:10.1001/jama.287.7.869
Author Affiliations: Departments of Pediatrics (Drs Freedman, Afonja, Chang, Lazarus, Schacht, Guttenberg, Traister, and Borkowsky), Dermatology (Dr Chang), Health (Dr Mostashari), and Medicine (Drs Blaser and Perez-Perez), New York University School of Medicine, New York.
A 7-month-old infant with cutaneous anthrax developed severe systemic
illness despite early treatment with antibiotics. The infant displayed severe
microangiopathic hemolytic anemia with renal involvement, coagulopathy, and
hyponatremia. These findings are unusual with cutaneous anthrax, but have
been described in illness resulting from spider toxin and may delay correct
diagnosis. The systemic manisfestations of the disease persisted for nearly
a month despite corticosteroid therapy, but resolved.
Anthrax infection is caused by Bacillus anthracis, an aerobic, spore-forming, gram-positive rod found throughout the
world, and presents in 3 forms: cutaneous, inhalational, and gastrointestinal.
The term anthrax, from the Greek anthrakos, meaning
coal, derives from the characteristic lesion of the cutaneous form, a black
eschar. Cutaneous anthrax accounts for approximately 95% of cases,1 while inhalational anthrax, the traditional woolsorter's
disease, is less common, and gastrointestinal anthrax is rare.2,3
However, all forms can lead to bacteremia, sepsis, meningitis, and death,
and all of these manifestations can occur in children.
Anthrax remains endemic in many parts of the world, including Asia,
Africa, South America, and Australia, and it is estimated that up to 20 000
cases occur annually.4 In contrast, 224 cases
of cutaneous anthrax were reported in the United States from 1944 to 2000,
and only 5 between 1984 and 2000.5,6
Furthermore, only 18 cases of inhalational anthrax occurred in the United
States during the 20th century, the last in 1978, and cases of gastrointestinal
anthrax have not been reported in the United States.2
None of these 20th-century cases were reported in children.
Since October 4, 2001, the epidemiological picture of anthrax in the
United States has changed considerably. In addition to bioterrorism-related
exposures to anthrax spores in various locations around the country, verified
cases of both pulmonary and cutaneous anthrax have been reported, including
several deaths. With 2 exceptions, all cases occurred in adults, whose exposure
took place in the context of their work in journalism, government, or postal
service.7 We report a case of cutaneous anthrax
with systemic complications that occurred in a 7-month-old infant. Although
a photograph and magnetic resonance image of this infant have previously been
published,8 this article includes detailed
clinical information describing this patient's complicated course.
A 7-month-old, previously healthy, white male infant was admitted to
the hospital on October 1, 2001. Two days prior to admission he was noted
to have a painless red macule on the proximal medial aspect of the left upper
extremity with associated swelling. During the next 24 hours, the arm became
increasingly edematous, the macule evolved to a papule, and a slight serous
drainage began. However, the patient remained afebrile and without apparent
pain or other systemic symptoms. His primary pediatricians treated him with
amoxicillin/clavulanate potassium for presumed cellulitis, but he required
admission to the hospital after the third dose, due to increased swelling
and drainage of the lesion, and his difficulty in tolerating oral medication.
The infant did not have a significant medical history but he had recently
played outdoors in a New York park and had also visited his mother at her
workplace, the offices of a national television news organization, for an
hour the day before his symptoms began. Anthrax spores were subsequently found
at his mother's workplace.
On admission, the infant was alert, afebrile, and in no apparent distress.
Laboratory studies revealed significant leukocytosis and hyponatremia (Table 1). Blood was not sent for culture,
but intravenous ampicillin/sulbactam was initiated. Surgical incision and
drainage performed under local anesthesia revealed no underlying abscess,
but dark red fluid was expressed from the lesion. Bacterial cultures were
On hospital day 2, the left arm showed massive, nonpitting, nontender
edema with a dark red macule approximately 2 to 3 cm in diameter. There was
copious, yellow serous drainage from the wound and paler erythema extending
across the anterior thorax to the sternum. No axillary adenopathy was palpable.
The hyponatremia was managed with fluid restriction and clindamycin was added
to the antibiotic regimen. An infectious disease consultation was obtained.
A gram stain of the wound drainage showed neither white blood cells nor organisms.
Differential diagnoses considered were infection of bone, soft tissue, or
both; arachnid bite; and obstructive mass lesion. Ultrasound of the left upper
extremity revealed diffuse inflammation without abscess, and minimal axillary
lymphadenopathy. Doppler studies excluded deep vein thrombosis or other vascular
compromise to the limb. Later that day, the patient became febrile (39.2°C)
and developed significant thrombocytopenia.
During the next 2 days, the arm edema decreased slightly, a 3-mm area
of central necrosis was noted at the wound site, and petechiae appeared on
the left anterosuperior thorax and axilla. The patient's hematocrit decreased
to 23.3%, and low-grade fever, hyponatremia, thrombocytopenia, and leukocytosis
persisted, now with a significant number of band forms. Due to loss of intravenous
access, the antibiotic regimen was changed to oral cephalexin and clindamycin.
By hospital day 5, the fever resolved and the arm edema had decreased
considerably. The lesion appeared as a circumscribed erythematous plaque (4.5
× 5 cm) with a central eschar of less than 1 cm (Figure 1A). A magnetic resonance image of the upper extremity (previously
published8) revealed extensive soft tissue
inflammation extending from the left lateral chest wall to the hand, but there
was no bone involvement, soft tissue gas or fluid collection, or mass lesion.
The hematocrit decreased to 18.7%. The glucose-6-phosphate dehydrogenase enzyme
level was normal, but the peripheral blood smear revealed schistocytes and
fragmented red blood cells. A serum lactate dehydrogenase level of greater
than 5000 U/L, along with evidence of mild increases in serum urea nitrogen
and creatinine levels, supported a diagnosis of microangiopathic hemolytic
At this point, the working diagnosis was cutaneous and systemic loxoscelism,
as the clinical course and the evolution of the skin lesion (Figure 1A) seemed more consistent with envenomation than an infectious
process. Dermatologic consultation concurred with this diagnosis. Oral prednisolone
was begun and antibiotics were discontinued.
While the patient's arm edema improved and he remained afebrile, his
hematologic status worsened during the next few days. The hematocrit decreased
to 14.3% with accompanying tachycardia, necessitating 2 transfusions of 15
mL/kg of packed red blood cells. Coagulopathy was evident, with ongoing thrombocytopenia
and elevated D-dimer levels and fibrin degradation products. A persistent
hypofibrinogenemia required transfusion of 4 U of cryoprecipitate. Renal insufficiency,
with elevated serum urea nitrogen, hematuria, proteinuria, transient oliguria,
and hypertension (systolic blood pressure of 130 mm Hg and diastolic blood
pressure of 85 mm Hg), were present. By hospital day 12, these laboratory
abnormalities were resolving and the patient was clinically stable. However,
a 2-cm black eschar was present in the center of the cutaneous lesion (Figure 1B).
That day, the first case of cutaneous anthrax in New York was reported
and the New York Department of Health was notified that this infant was potentially
infected with anthrax. Two skin biopsies of the lesion were performed the
next day, and these, as well as blood obtained on hospital day 2, were sent
to the Centers for Disease Control and Prevention for polymerase chain reaction
diagnosis and immunohistology, respectively. Two days later, these tests were
reported as positive for B anthracis, with significant
anthrax DNA present in the serum sample and immunohistochemical detection
of fragmented anthrax bacilli in the biopsy tissue. Western blot testing of
serum samples from day 13 of illness revealed both an IgM response to the
83-kd protective factor and an IgG response (Figure 2).
On day 20 of the patient's illness, the IgM response decreased but the
IgG response intensified and extended to the edema and lethal factors band
of 89 to 93 kd. The patient was discharged home on day 17 of illness, receiving
oral ciprofloxacin, the treatment recommended by the Centers for Disease Control
and Prevention. His platelet count and fibrinogen level were normal, but evidence
of a mild hemolysis persisted. After 2 weeks of ciprofloxacin, when the other
anthrax isolates were shown to be susceptible to penicillin, amoxicillin was
used as the antibiotic. Hematuria, anemia, and elevated D-dimer levels slowly
resolved over the next 2 weeks, 30 days after admission. Serum urea nitrogen
and creatinine levels were normal at 12 days after admission and the skin
lesion healed with little evidence of scarring by day 60 (Figure 1C).
Cutaneous anthrax is primarily a local infection and may resolve spontaneously.
Untreated cutaneous anthrax may cause systemic disease with up to 20% mortality,9 although with antibiotic treatment the mortality rate
is less than 1%.10 Antibiotic treatment has
been reported to sterilize the skin lesion within 24 hours10;
thus prompt institution of antibiotics appears to limit hematogenous spread
of the organism, but does not change the local, toxin-mediated effects. Signs
of systemic infection may range from fever and leukocytosis to septic shock,
meningitis, and death.
Cutaneous anthrax in children is reported less frequently than in adults;
a review of MEDLINE revealed 30 case reports between 1967 and 2001, mostly
in rural settings in developing nations. The disease has been reported in
neonates, children, and adolescents. While infants and young children may
acquire anthrax from infected bedding or other fomites, 2 reports suggest
that skin-to-skin contact may be an important route of transmission in this
age group. One case involved an infant whose mother had an anthrax lesion
on her cheek,11 the other involved 2 young
children who slept in the same bed.12 In another
case series of 11 patients with periocular anthrax, 6 children were younger
than 6 years. The authors speculate that young children may be more likely
to rub their eyes with spore-contaminated fingers or to have spore-carrying
insects swarm on their eyelids.13 The origin
of cutaneous anthrax in the infant described in this article is probably related
to the finding of anthrax spores at the mother's workplace. One possible scenario
is that spores present on the hands of someone in the workplace who lifted
or held the child may have contacted an exposed or possibly abraded area of
the child's skin.
The clinical presentation of cutaneous anthrax in children as reported
in the literature is similar to that in adults, with an initial painless papulovesicular
lesion surrounded by massive interstitial edema, which develops an eschar
within 2 to 5 days. Children also can develop systemic symptoms, such as fever
and leukocytosis, particularly if treatment is delayed and bacteremia develops.
A review of cases from the first half of the 20th century reveals that more
than half of anthrax meningitis cases in children were preceded by cutaneous
disease.14 While the patient described in this
article had a fairly typical clinical course with respect to the cutaneous
lesion, several features of this case have not, to our knowledge, been described
previously in the context of cutaneous anthrax.
First, this child's illness was complicated by severe hematologic abnormalities
requiring multiple transfusions of blood products. Between admission and hospital
day 6, he developed a severe microangiopathic hemolytic anemia with significant
thrombocytopenia, renal involvement, and coagulopathy. To date, there has
been only 1 case report of coagulopathy resulting from cutaneous anthrax.
In this case, a 20-year-old Iranian woman with cutaneous anthrax developed
septic shock associated with thrombocytopenia, hypofibrinogenemia, elevated
fibrin degradation products, and elevated prothrombin time,9
with associated hematuria, hypoproteinemia, and hyperkalemia. In another report,
involving a 57-year-old British man, the patient had a normal hematologic
profile but developed elevated creatine kinase levels and renal failure.15 Neither of these patients exhibited the combination
of acute hemolysis, coagulopathy, and renal insufficiency found in the patient
Second, the patient developed persistent hyponatremia, which required
careful fluid management during his hospital course. Electrolyte abnormalities,
particularly hyperkalemia, occasionally have been described in patients with
cutaneous anthrax, usually in connection with severe sepsis and shock. Mild
hyponatremia has been noted in 5 of the 10 individuals with bioterrorism-related
inhalational anthrax.16 Hyponatremia in this
infant coincided with the massive edema of his left upper extremity and was
probably related to the degree of fluid shift in his 7-month-old body, something
that might not be seen in a larger child or an adult. The hyponatremia began
to resolve with the administration of corticosteroids, which have been reported
to be beneficial in the treatment of the edema associated with anthrax.17
Third, the patient had severe systemic symptoms despite timely institution
of antibiotic and corticosteroid therapy. Most case reports suggest that cutaneous
anthrax in children is, for the most part, a mild infection, with few serious
consequences provided that treatment with antibiotics is provided.18,19 Mortality and significant morbidity
are consistently described as the result of delay in treatment and are proportional
to the clinical status of the patient at presentation. Occasionally, bacteremia
or meningitis occurs in children with cutaneous disease.2
In this patient, systemic signs occurred 36 to 48 hours after antibiotics
were started. Bacterial DNA was detected in a peripheral blood sample suggesting
that significant bacteremia or circulating toxin was already present, despite
the patient remaining afebrile and having largely normal laboratory values.
The role of surgical debridement in the dissemination of bacteria or toxin
Fourth, many of the signs and symptoms, including edema, fever, leukocytosis,
thrombocytopenia, hemolysis, renal failure, and disseminated intravascular
coagulation, while rarely associated with cutaneous anthrax, are associated
with envenomations, particularly that of Loxosceles reclusa.20,21 Although this spider
has rarely been found in New York, cutaneous anthrax had never before been
diagnosed in an infant prior to October 200l.
Possibly the most useful clinical features for distinguishing anthrax
from other diagnoses, such as cellulitis or insect bite, are the relatively
large extent of the associated edema and the painlessness of the lesion. The
culture of the organism from a site of inflammation prior to the initiation
of antibiotics is a diagnostic response. Serological responses to anthrax
toxins, particularly the protective antigen, have previously been used to
define infection in humans and animals. One study in humans found that only
24% of infected individuals had detectable antiprotective antigen antibodies
within the first week of infection. This increased to 83% when a serum sample
was obtained after the first week.22 Only 1
report has compared serological responses in children and adults.23 In this case, antibodies were seen in 8 of 17 adults
and in 2 of 8 children, with much lower titer levels in children, suggesting
that they may be less responsive than adults. The infant in this article had
evidence of an evolving primary immune response, particularly to the protective
antigen, by day 13 of illness on Western blot. We hypothesized that the prolonged
evidence of hemolysis may have been due to the absence of antibody production
to the toxins. The kinetics of the response did correlate with the increase
in platelets but not with the ongoing hemolysis.
As this case illustrates, cutaneous anthrax in an infant or child may
quickly progress to a severe systemic disease; thus, if the diagnosis is suspected,
the patient should be admitted to the hospital, electrolyte and hematological
status should be monitored carefully, and intravenous antibiotics should be
instituted. A presumptive diagnosis can be made by blood culture or Gram stain
prior to initiating antibiotics, or more definitively by serum polymerase
chain reaction and skin biopsy. Although the strain of anthrax recovered from
the recent US cases is susceptible to penicillin, doxycycline, and fluoroquinolones,
the use of the latter 2 drugs in young children is potentially problematic.
After this infant was diagnosed, it was recommended that he be treated with
ciprofloxacin for the remainder of the 60 days from the onset of infection,
as per the initial recommendations of the Centers for Disease Control and
Prevention.24 Fluoroquinolones are theoretically
toxic to developing cartilage but the American Academy of Pediatrics recommends
their use, as the benefits outweigh the risks.25
Doxycycline is another option despite its propensity to stain the enamel of
developing teeth. The Centers for Disease Control and Prevention now recommends
that a second antibiotic be added to the initial therapy of systemic disease.7 The addition of clindamycin to this infant's therapy
may have provided additional benefit. Although ciprofloxacin was initiated
once the diagnosis was established, therapy was changed to amoxicillin after
a week because of concerns about potential toxicity and since the organism
was sensitive to this agent.26
In this new era of bioterrorism, anthrax should be considered in the
differential diagnosis of acute progressive inflammatory disorders of the
skin as well as the other syndromes with which it is associated.